Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study

Tremblay and colleagues asked whether patients receiving either routine anticoagulation or antiplatelet therapy for existing conditions prior to becoming ill with COVID-19 have different outcomes from patients receiving neither therapy. After matching for existing comorbidities, this retrospective o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Douglas, van Gerwen, Maaike, Alsen, Mathilda, Thibaud, Santiago, Kessler, Alaina, Venugopal, Sangeetha, Makki, Iman, Qin, Qian, Dharmapuri, Sirish, Jun, Tomi, Bhalla, Sheena, Berwick, Shana, Feld, Jonathan, Mascarenhas, John, Troy, Kevin, Cromwell, Caroline, Dunn, Andrew, Oh, William K., Naymagon, Leonard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. 2020
Materias:
Letters to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332896/
https://www.ncbi.nlm.nih.gov/pubmed/32462179
http://dx.doi.org/10.1182/blood.2020006941
Descripción
Sumario:Tremblay and colleagues asked whether patients receiving either routine anticoagulation or antiplatelet therapy for existing conditions prior to becoming ill with COVID-19 have different outcomes from patients receiving neither therapy. After matching for existing comorbidities, this retrospective observational study finds no evidence for an effect of prediagnosis anticoagulation on mortality.

Ejemplares similares